| Project/Area Number |
24791099
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Research Institute for Clinical Oncology, Saitama Cancer Center |
|---|
Principal Investigator |
MASAYUKI Haruta 埼玉県立がんセンター(臨床腫瘍研究所), その他部局等, 研究員 (80392190)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 腎芽腫 / 予後因子 / WTX / 予後予測因子 |
|---|
| Research Abstract |
In nephroblastoma, identification of new prognostic markers for better therapy planning are needed to improve the mortality and recurrence rate, and prevent side and late effects. In this study, we examined genetic and epigenetic abnormalities of the 5 genes ( WT1, CTNNB1, WTX, TP53 and IGF2) and DNA methylation status of three tumor suppressor genes ( RASSF1A, DCR2 and CASP8) in Japanese nephroblastoma. WTX mutation and RASSF1A hypermethylation was correlated with poor prognosis by Kaplan-Meier analysis (p=0.040 and p=0.043, respectively). Nephroblastoma patients with both WTX and TP53 mutation particularly showed poor prognosis.
|
